NewAmsterdam Pharma Company NV (NASDAQ: NAMS)’s stock price has gone rise by 0.94 in comparison to its previous close of 23.36, however, the company has experienced a 0.34% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-02-28 that New Amsterdam Pharma’s obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to file for European approval in 2025, with ongoing trials potentially confirming additional cardiovascular benefits. Despite competition, obicetrapib’s oral administration and lack of side effects position it favorably against injectable PCSK9 inhibitors.
Is It Worth Investing in NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Right Now?
Moreover, the 36-month beta value for NAMS is -0.09. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NAMS is 56.66M and currently, short sellers hold a 5.37% of that float. On March 14, 2025, NAMS’s average trading volume was 813.39K shares.
NAMS’s Market Performance
NAMS stock saw an increase of 0.34% in the past week, with a monthly gain of 23.52% and a quarterly increase of 27.32%. The volatility ratio for the week is 5.97%, and the volatility levels for the last 30 days are 6.74% for NewAmsterdam Pharma Company NV (NAMS). The simple moving average for the last 20 days is 12.73% for NAMS’s stock, with a simple moving average of 18.49% for the last 200 days.
Analysts’ Opinion of NAMS
Many brokerage firms have already submitted their reports for NAMS stocks, with H.C. Wainwright repeating the rating for NAMS by listing it as a “Buy.” The predicted price for NAMS in the upcoming period, according to H.C. Wainwright is $48 based on the research report published on December 30, 2024 of the previous year 2024.
Scotiabank gave a rating of “Sector Outperform” to NAMS, setting the target price at $35 in the report published on March 14th of the previous year.
NAMS Trading at 6.36% from the 50-Day Moving Average
After a stumble in the market that brought NAMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.59% of loss for the given period.
Volatility was left at 6.74%, however, over the last 30 days, the volatility rate increased by 5.97%, as shares surge +21.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.82% lower at present.
During the last 5 trading sessions, NAMS rose by +0.34%, which changed the moving average for the period of 200-days by +23.46% in comparison to the 20-day moving average, which settled at $20.92. In addition, NewAmsterdam Pharma Company NV saw -8.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NAMS starting from Topper James N, who purchase 4,005 shares at the price of $21.02 back on Mar 04 ’25. After this action, Topper James N now owns 3,012,434 shares of NewAmsterdam Pharma Company NV, valued at $84,203 using the latest closing price.
Kooij Louise Frederika, the Chief Accounting Officer of NewAmsterdam Pharma Company NV, sale 150,000 shares at $20.37 during a trade that took place back on Mar 04 ’25, which means that Kooij Louise Frederika is holding 15,000 shares at $3,055,500 based on the most recent closing price.
Stock Fundamentals for NAMS
Current profitability levels for the company are sitting at:
- -3.71 for the present operating margin
- 1.0 for the gross margin
The net margin for NewAmsterdam Pharma Company NV stands at -5.12. The total capital return value is set at -0.22.
Based on NewAmsterdam Pharma Company NV (NAMS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -337.25. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 305.7.
Currently, EBITDA for the company is -241.49 million with net debt to EBITDA at 3.22. When we switch over and look at the enterprise to sales, we see a ratio of 40.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.08.
Conclusion
To wrap up, the performance of NewAmsterdam Pharma Company NV (NAMS) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
